Feb 1, 2022 8:30 am EST Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
Jan 10, 2022 7:00 am EST Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
Dec 15, 2021 8:30 am EST Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
Oct 21, 2021 8:30 am EDT Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
Oct 12, 2021 1:35 pm EDT Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
Oct 7, 2021 9:00 am EDT Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
Sep 29, 2021 4:30 pm EDT Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering